Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy
Authors:
- Kaku ItohKIKaku Itoh
- Misaki NegishiMNMisaki Negishi
Open Access
- 1 March 2026
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Abstract
Purpose: To compare and evaluate, across different agents, the risk of intraocular pressure (IOP) elevation after anti-VEGF therapy and the accuracy of prefilled syringes. Methods: Total of 175 eyes treated with anti-VEGF drugs were enrolled for this study. An accuracy evaluation of the prefilled syringes was conducted involving 25 participants, comprising 17 physicians and 8 nurses. The anti-VEGF agents including aflibercept 2 mg, aflibercept 8 mg, brolucizumab, faricimab, and ranibizumab-BS were assessed. IOP was measured before, and at 1 and 15 minutes after intravitreal injection, and analyzed separately for each drug. Furthermore, prefilled syringes of aflibercept 2 mg, brolucizumab, and ranibizumab-BS, as well as 1-mL syringes filled with saline solution, were equipped with 30-gauge needles, followed by careful removal of air. The weight of the saline discharged according to the scale marking was measured using an electronic balance. Results: At 1 min after intravitreal injection, the IOP was highest in the aflibercept 2 mg group, with a mean value of 52.8 mmHg. A mild inverse correlation was observed between axial length and IOP elevation at 1 min post-injection, suggesting that eyes with longer axial length exhibited less pronounced IOP increases. In the syringe accuracy analysis, the prefilled syringe of aflibercept 2 mg expelled a significantly larger volume, with a mean of approximately 0.076 mL, compared to other prefilled syringes. Conclusion: Intravitreal injection using the aflibercept 2 mg prefilled syringe may deliver approximately 1.5 times the intended volume into the eye. This may raise safety concerns, such as the risk of transient vision loss due to marked immediate IOP elevation, and may also affect clinical outcomes and the validity of clinical trials.Keywords
This publication has 29 references indexed in Scilit:
- ACCURACY AND PRECISION OF INTRAVITREAL INJECTIONS OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN REAL LIFERetina, 2019
- Anti–Vascular Endothelial Growth Factor Agents in the Treatment of Retinal DiseaseOphthalmology, 2016
- Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation ProceduresEuropean Journal of Ophthalmology, 2015
- Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and CorrelationsJournal of Current Glaucoma Practice, 2013
- A Brief History of Anti-VEGF for the Treatment of Ocular AngiogenesisThe American Journal of Pathology, 2012
- Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: A Prospective StudyActa Ophthalmologica, 2012
- Impaired Retinal Circulation in Patients with Type 2 Diabetes Mellitus: Retinal Laser Doppler Velocimetry StudyInvestigative Ophthalmology & Visual Science, 2010
- Short-term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti–Vascular Endothelial Growth Factor AgentsAmerican Journal of Ophthalmology, 2008
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006